National Institute of Oncology develops TIL therapy. Plans cover several types of cancer
The National Institute of Oncology is working on a cell therapy using tumor-infiltrating T lymphocytes (TIL). It is the first centre in this region of Europe to work with this method. Its use is planned for treating several types of cancer.

- 0views
- 0likes and saves
- 0skips
In brief
- The National Institute of Oncology is developing cell therapy using TIL lymphocytes.
- The institute is the first center in this region of Europe working on this method.
- The therapy is intended to cover the treatment of several types of cancer; no implementation dates have been given.
A new treatment method in Warsaw
The National Institute of Oncology is developing TIL therapy, i.e., tumor-infiltrating lymphocytes. Prof. Piotr Rutkowski from this institution told PAP that the institute is the first in this region of Europe conducting work on this method (Polska chce rozwijać terapie komórkowe. W planach leczenie kilku rodzajów raka – Bankier.pl). Cell therapies are among the newest directions in cancer treatment, and TIL is one of their latest examples.
How TIL works
The method is based on the patient's own immune cells that are found in the tumor. Lymphocytes are collected from the cancer, then multiplied outside the body and administered to the patient to strengthen their response to the disease.
Plans for further cancers
The plans include applying the therapy to the treatment of several types of cancer. At this stage, no implementation dates or number of patients who could benefit from it have been provided.
Sources
Discussion0
- No comments from this perspective yet. Be the first.